@nisimisc, Yes, it has allot of potential (IMO, with groundbreaking technology);however, it's heavily shorted... catalyst is approval of COVI-TRACK (accessdata.fda.gov/scripts/cdrh/Cfdocs/cfrl/rl.cfm?lid=691172&;lpcd=QKP). Fundamentally Sorrento owns the largest proprietary library of human antibodies. The antibodies that humans have shown that best match/fit the spike protein and invade it. If what they claim works... well use your imagination ... it's posted in their site